EA200501569A1 - Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина - Google Patents

Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина

Info

Publication number
EA200501569A1
EA200501569A1 EA200501569A EA200501569A EA200501569A1 EA 200501569 A1 EA200501569 A1 EA 200501569A1 EA 200501569 A EA200501569 A EA 200501569A EA 200501569 A EA200501569 A EA 200501569A EA 200501569 A1 EA200501569 A1 EA 200501569A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tymosine
peptides
alpha
prevention
treatment
Prior art date
Application number
EA200501569A
Other languages
English (en)
Other versions
EA009945B1 (ru
Inventor
Алфред Р. Рудолф
Синтия У. Татхилл
Original Assignee
Сциклон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сциклон Фармасьютикалс, Инк. filed Critical Сциклон Фармасьютикалс, Инк.
Publication of EA200501569A1 publication Critical patent/EA200501569A1/ru
Publication of EA009945B1 publication Critical patent/EA009945B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Пептид альфа-тимозин вводят больному, имеющему или рискующему получить респираторную вирусную инфекцию, коронавирусную инфекцию и/или тяжелый острый респираторный синдром (ТОРС).
EA200501569A 2003-04-23 2004-04-23 Способ лечения или профилактики респираторной коронавирусной инфекции с использованием пептидов альфа-тимозина EA009945B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46464503P 2003-04-23 2003-04-23
US47042003P 2003-05-15 2003-05-15
PCT/US2004/012663 WO2004094991A2 (en) 2003-04-23 2004-04-23 Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Publications (2)

Publication Number Publication Date
EA200501569A1 true EA200501569A1 (ru) 2006-06-30
EA009945B1 EA009945B1 (ru) 2008-04-28

Family

ID=33313489

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501569A EA009945B1 (ru) 2003-04-23 2004-04-23 Способ лечения или профилактики респираторной коронавирусной инфекции с использованием пептидов альфа-тимозина

Country Status (12)

Country Link
US (1) US20070036744A1 (ru)
EP (1) EP1635854A4 (ru)
JP (1) JP2006524704A (ru)
KR (1) KR20060013515A (ru)
AU (1) AU2004232847B2 (ru)
BR (1) BRPI0409711A (ru)
CA (1) CA2522891A1 (ru)
EA (1) EA009945B1 (ru)
MX (1) MXPA05011304A (ru)
NO (1) NO20055512L (ru)
NZ (1) NZ543651A (ru)
WO (1) WO2004094991A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
PL2012816T3 (pl) * 2006-05-02 2012-11-30 Sigma Tau Ind Farmaceuti Zastosowanie tymozyny 1, samej lub w kombinacji z ptx3 lub gancyklowirem, do leczenia zakażenia cytomegalowirusem
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN111671886B (zh) * 2020-03-05 2022-11-15 上海甘翼生物医药科技有限公司 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy

Also Published As

Publication number Publication date
AU2004232847A1 (en) 2004-11-04
EP1635854A2 (en) 2006-03-22
AU2004232847B2 (en) 2008-11-20
BRPI0409711A (pt) 2006-05-02
CA2522891A1 (en) 2004-11-04
NZ543651A (en) 2007-01-26
KR20060013515A (ko) 2006-02-10
JP2006524704A (ja) 2006-11-02
MXPA05011304A (es) 2005-12-12
US20070036744A1 (en) 2007-02-15
WO2004094991A3 (en) 2004-12-16
EA009945B1 (ru) 2008-04-28
WO2004094991A2 (en) 2004-11-04
NO20055512L (no) 2005-11-22
EP1635854A4 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CY1109216T1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
CO5241354A1 (es) Terapia de combinacio para vhc
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
HUP0301444A2 (hu) Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására
TW200733953A (en) Materials and methods for treating viral infections
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
RU2010153688A (ru) Режим дозирования телапревира
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
NO20055243L (no) Interferon beta ved alvorlig akutt respiratorisk syndrom (SARS)
SG169362A1 (en) Treatment or prevention of respiratory viral infections with immunomodulator compounds
DK1350510T3 (da) Anvendelse af et middelt til undertrykkelse af infektion og proliferation af humant immundefektvirus
DE602005022612D1 (de) Behandlung oder prävention von hämorrhagischen virusinfektionen mit immunomodulatorischen verbindungen
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
WO2004006848A3 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
PL356897A1 (en) High stability bacteriophage preparation and application of block copolymer of ethyl oxide and propylene oxide
WO2024049790A3 (en) Composition for pattern recognition based targeting and activating an innate immune response

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU